Predictive Protein Biomarker-based Treatment
Decision Support
Pathway-based assessement of the activated proteome using Reverse Phase Protein Array (RPPA) and laser capture microdissection (LCM) to support therapeutic development in oncology and immuno-oncology from discovery through clinical trials.
Patented Technology Offering:
Coverage
~700 proteins/phosphoproteins across key canonical pathways
Quantification
RPPA enables detection of up to 500X dynamic range¹
Translatability
Homogenous assay from research to clinic
Sensitivity
Can detect 100 analytes from just 10,000 cells per experiment
Customization
Ability to quickly add your targets and accept multiple sample inputs (tissues (FFPE/frozen) and cells)
Predictivity
Proteomic biomarkers are more predictive than genomics²